Besides, we also proved that high-ITGA5 gliomas were accompanied by high immunotherapy biomarker expression, namely, PD-1, PD-L1, CTLA-4, and VEGF, thus showing an ITGA5-targeted therapeutic potential to be synergistic with immunotherapy. The gene discussed is PDCD1; the disease is glioma.